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n the United States, the incidence of melanoma
is increasing faster than any other preventable
cancer. Acral melanoma is the fourth most
common type of cutaneous melanoma and is
frequently diagnosed later in its course compared
with melanoma in other anatomic locations. Here we
describe a case of highly advanced acral melanoma.
CASE REPORT
A 47-year-old Caucasian man presented to the
dermatology department for evaluation of a mass on
his left foot. Six years prior, the patient had dropped
a sledgehammer on his left great toe causing
significant toenail damage, nail loss, and enlarging
ulceration despite meticulous wound care. Ten
months before presentation, the patient noted rapid
growth of the left great toe mass that began to
encompass the majority of the distal aspect of his
foot. As the mass grew, the patient reported
foul-smelling discharge, tissue sloughing, and
bleeding. Three months before presentation, a
mass appeared in the patient’s left groin, along
with scattered firm nodules on the left calf and thigh.
The patient had not sought medical care for the mass
other than 1 visit to the emergency department
2 months prior, during which the patient declined
oncology consultation. He attributed his reluctance
to seek medical care to lack of insurance and his
belief that the growth was caused by an infection.
On examination, the patient had a 30- 3 17-cm
fungating, irregularly shaped necrotic mass
engulfing his great toe and the majority of the distal
medial aspect of his foot (Fig 1). There were multiple
violaceous subcutaneous nodules along the thigh
and a 15-cm firm, bound-down mass in the left grointhe Departments of Dermatologya and Pathology,b Univer-
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ail: Mariah.brown@ucdenver.edu.along with pronounced edema of the entire left
extremity. The patient appeared pale and cachectic.
A biopsy specimen of the left toe mass and a left leg
nodule confirmed the diagnosis of primary
melanoma and metastatic melanoma. Histology
demonstrated highly atypical S1001 epithelioid cells
with prominent perineural invasion (Fig 2). Positron
emissionecomputed tomography showed a mass
with bony invasion causing destruction of the left
hallux, enlarged inguinal, retroperitoneal, pulmo-
nary, mediastinal, and supraclavicular lymph nodes
and pulmonary nodules. Laboratory analyses
showed numerous abnormalities. The patient had
severe anemia with a hemoglobin of 6.3 g/dL
(normal range 14.3-18.1 g/dL) and hematocrit of
22% (39.2%-50.2%). White blood cell count and
platelets were elevated at 12.1 109/L (4.0-11.1
109/L) and 701 109/L (150-400 109/L), respectively.
C-reactive protein and erythrocyte sedimentation
rate were elevated at 15.4 mg/dL (0.0-1.0 mg/dL)
and 124 mm/h (0-10 mm/h), respectively. Liver
function tests showed evidence of malnutrition
with an albumin of 2.3 g/dL (3.4-5.0 g/dL). Basic
metabolic panel and lactate dehydrogenase were
within normal limits. Genetic analysis of tumor tissue
was negative for BRAF, NRAS, and c-kit mutations.
The left foot mass was partially surgically excised by
the podiatry department to improve the patient’s
overall quality of life. The patient was then enrolled
in a blinded clinical trial of a combination of an
antibody against programmed cell death protein 1
and ipilimumab, an anticytotoxic T-lymphocyte-
associated protein 4 antibody versus monotherapy
of both agents. He was enrolled into one of the
monotherapy arms of the trial and received onlyJAAD Case Reports 2015;1:166-8.
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Fig 1. A to C, Acral melanoma. Clinical presentation of large, fungating, malodorous mass
obscuring the left great toe with large areas of necrosis. D, Firm, lobulated mass in left groin.
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Lambert Smith, Wisell, and Brown 167ipilimumab at a dose of 3 mg/kg. Unfortunately, after
just 2 doses of ipilimumab, the patient experienced
severe colitis, a known immune-related adverse
event, resulting in hospitalization and drug discon-
tinuation. Once removed from the medication, the
patient’s colitis resolved and he elected to receive
hospice care. He died of his metastatic disease
4 months after initial presentation.
DISCUSSION
It is estimated that in 2014 more than 76,000
people were diagnosed with invasive melanoma and
greater than 9000 people died of this disease.1 Acral
melanomas account for only 1% of all cutaneous
melanomas, but are frequently associated with a
poorer prognosis. Acral melanomas have been
shown to have significantly decreased 5-yearsurvival (52%) than matched counterparts with
melanoma on the leg (85%).2 Acral melanomas on
the foot compared with those on the hand have also
been associated with decreased survival.3 This poor
prognosis is likely multifactorial. Patients often
attribute pedal melanomas to prior trauma and it is
unclear whether or not trauma may have a causative
role or simply brings attention to an existing lesion.3
Trauma can further delay diagnosis if pigment is
mistaken for subungual hemorrhage. Bob Marley,
who was diagnosed with acral melanoma in 1977,
was known to have a soccer injury to the same region
a few months before his diagnosis.4,5 Physicians also
misdiagnose acral melanomas up to 33% of the time,
with an average time to diagnosis of 13.5 months
from the first recognition of the lesion.6 Finally, it is
questioned whether or not acral melanoma is an
Fig 2. Pathology of acral melanoma. A, Histologically the lesion is densely cellular with
minimal intervening stroma. B and C, Higher-power magnification demonstrates epithelioid
tumor cells with marked cellular and nuclear atypia. D, An immunohistochemical study for
S100 strongly and diffusely labels the tumor cells. (Original magnification: 340.) (A to C,
Hematoxylin-eosin stain; original magnifications: A, 340; B, 3100; C, 3200.)
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Our patient demonstrates the natural progression
of advanced acral melanoma, with a large and
destructive primary tumor and diffuse metastatic
disease at the time of presentation. The unfortunate
combination of decreased access to health care,
delayed diagnosis, neglect, and acral location led to
a 6-year growth of the primary tumor and eventual
death from metastatic disease.
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